ZYBERNO
Stock Report
Updated Aug 29, 2026

VAXCYTE, INC. (PCVX)

Healthcare • NASDAQ

$59.84
Vaxcyte Inc. is an American clinical-stage vaccine innovation company headquartered in San Carlos, California, that uses cell-free protein synthesis to design and engineer high-fidelity biologics. The company's lead program VAX-24 is a 24-valent pneumococcal vaccine candidate designed to provide broader protection against pneumococcal disease than existing 13- and 20-valent vaccines from Pfizer and Merck.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
VAXCYTE, INC. (PCVX) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-37.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-32.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VAXCYTE, INC. (PCVX) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, PCVX generated -$779.56M in Owner Earnings. Capital was deployed as follows: $10.40M invested in capital expenditures. Reinvestment rate: 0.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:59.84
Market Cap:$8.65B

Valuation Multiples (2)

P/B Ratio:3.13x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.58B

Price Action & Momentum (3)

Momentum Percentile:89 / 100
% of 52-Week High:92.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-33.6%
Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$13.11
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-35.0%
Latest Earnings Filed:2026-08-05
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.72x
Quick Ratio:5.72x
Cash Ratio:0.68x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:1,281,391,000.00
Cash And Cash Equivalents:183,190,000.00
Long Term Debt:$108.94M
Net Debt:-$67.75M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$1.17B

Bottom Line Performance (3)

-$1.06B
Income Before Tax:$0.00
Ebitda Ttm:-1,148,903,000.00

Operating Expenses (5)

Operating Expenses:1,165,290,000.00
R And D Expense:1,032,624,000.00
Sga Expense:132,666,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.14B
Current Assets:$1.55B
Ppe Net:260,390,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:380,212,000.00
Current Liabilities:271,277,000.00
Long Term Debt:$108.94M
Short Term Debt:$6.51M

Equity & Capital (3)

Equity:$2.76B
Retained Earnings:-$2.76B
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:100,919,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:37,964,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$769.93M-$780.32M

Investment Activities (2)

Investing Cash Flow:-$233.41M
Capital Expenditures Ttm:10,396,000.00

Financing Activities (3)

Financing Cash Flow:$601.58M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:195,943,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:16,387,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.64
-$7.64
Earnings Per Share Ttm:-$7.37

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$4.54

Book Value & Capital (2)

Book Value Per Share:$19.09
Cash Per Share:1.27

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$779.56M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):71.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:PCVX
Company Name:VAXCYTE, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:144.49M
Shares Outstanding Basic:144.49M
Shares Outstanding Diluted:144.49M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-29 01:11:06 UTC
Data Timestamp:2026-08-14T09:28:10.834129
Scroll to Top